These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9380259)

  • 21. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S; Cohen G
    Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?
    Ziv I; Barzilai A; Offen D; Nardi N; Melamed E
    J Neural Transm Suppl; 1997; 49():69-76. PubMed ID: 9266415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Factors which can play important role in pathogenesis of Parkinson disease].
    Koziorowski D; Jasztal J
    Neurol Neurochir Pol; 1999; 33(4):907-21. PubMed ID: 10612105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of Parkinson's disease.
    Schapira AH
    Baillieres Clin Neurol; 1997 Apr; 6(1):15-36. PubMed ID: 9426866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Morphometric assessment of lesions in the dopaminergic nigrostriatal system in Parkinson disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1996; 30(5):751-62. PubMed ID: 9148173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of specific dopaminergic neuronal death in Parkinson's disease].
    Ogawa N; Asanuma M; Miyoshi K
    Nihon Rinsho; 2004 Sep; 62(9):1629-34. PubMed ID: 15462376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 36. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
    Jenner P
    J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):22-8. PubMed ID: 2666576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidation reactions in Parkinson's disease.
    Olanow CW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 32-7; discussion 37-9. PubMed ID: 2215972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.